These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 26307001

  • 21. Microthrombotic Renal Vascular Lesions Are Associated to Increased Renal Inflammatory Infiltration in Murine Lupus Nephritis.
    Gonzalo-Gil E, García-Herrero C, Toldos O, Usategui A, Criado G, Pérez-Yagüe S, Barber DF, Pablos JL, Galindo M.
    Front Immunol; 2018; 9():1948. PubMed ID: 30210500
    [Abstract] [Full Text] [Related]

  • 22. Complement Properdin Determines Disease Activity in MRL/lpr Mice.
    Alaridhee H, Alharbi A, Saeed Z, Thomas RC, Stover CM.
    Medicina (Kaunas); 2020 Aug 27; 56(9):. PubMed ID: 32867176
    [Abstract] [Full Text] [Related]

  • 23. Nucleosomes contribute to increase mesangial cell chemokine expression during the development of lupus nephritis.
    Kanapathippillai P, Hedberg A, Fenton CG, Fenton KA.
    Cytokine; 2013 May 27; 62(2):244-52. PubMed ID: 23561928
    [Abstract] [Full Text] [Related]

  • 24. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
    Steinmetz OM, Turner JE, Paust HJ, Lindner M, Peters A, Heiss K, Velden J, Hopfer H, Fehr S, Krieger T, Meyer-Schwesinger C, Meyer TN, Helmchen U, Mittrücker HW, Stahl RA, Panzer U.
    J Immunol; 2009 Oct 01; 183(7):4693-704. PubMed ID: 19734217
    [Abstract] [Full Text] [Related]

  • 25. Glomerular Injury Is Exacerbated in Lupus-Prone MRL/lpr Mice Treated with a Protease-Activated Receptor 2 Antagonist.
    Itto R, Oe Y, Imaruoka K, Sato E, Sekimoto A, Yamakage S, Kumakura S, Sato H, Ito S, Takahashi N.
    Tohoku J Exp Med; 2019 Oct 01; 249(2):127-133. PubMed ID: 31666446
    [Abstract] [Full Text] [Related]

  • 26. Alleviation of renal disease and lymphadenopathy in MRL-Fasp(lrcg)/Fas(lprcg) (MR-lpr(cg)) mice neonatally infected with mouse mammary tumor virus encoding superantigen strongly reactive with TCR Vbeta8.2 element.
    Matsuzawa A, Yasuda T, Zhang Y, Nagase H, Yoshimoto T, Kimura M, Tsubura A.
    Viral Immunol; 2000 Oct 01; 13(3):297-311. PubMed ID: 11016595
    [Abstract] [Full Text] [Related]

  • 27. Treatment with a CD40 Antagonist Antibody Reverses Severe Proteinuria and Loss of Saliva Production and Restores Glomerular Morphology in Murine Systemic Lupus Erythematosus.
    Perper SJ, Westmoreland SV, Karman J, Twomey R, Seagal J, Wang R, McRae BL, Clarke SH.
    J Immunol; 2019 Jul 01; 203(1):58-75. PubMed ID: 31109957
    [Abstract] [Full Text] [Related]

  • 28. Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice.
    Schwarting A, Paul K, Tschirner S, Menke J, Hansen T, Brenner W, Kelley VR, Relle M, Galle PR.
    J Am Soc Nephrol; 2005 Nov 01; 16(11):3264-72. PubMed ID: 16221871
    [Abstract] [Full Text] [Related]

  • 29. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
    Werwitzke S, Trick D, Sondermann P, Kamino K, Schlegelberger B, Kniesch K, Tiede A, Jacob U, Schmidt RE, Witte T.
    Ann Rheum Dis; 2008 Feb 01; 67(2):154-61. PubMed ID: 17557887
    [Abstract] [Full Text] [Related]

  • 30. Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus.
    Mackern-Oberti JP, Obreque J, Méndez GP, Llanos C, Kalergis AM.
    Clin Exp Immunol; 2015 Oct 01; 182(1):1-13. PubMed ID: 26095291
    [Abstract] [Full Text] [Related]

  • 31. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells.
    Patole PS, Gröne HJ, Segerer S, Ciubar R, Belemezova E, Henger A, Kretzler M, Schlöndorff D, Anders HJ.
    J Am Soc Nephrol; 2005 May 01; 16(5):1326-38. PubMed ID: 15772251
    [Abstract] [Full Text] [Related]

  • 32. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.
    Pérez de Lema G, Maier H, Franz TJ, Escribese M, Chilla S, Segerer S, Camarasa N, Schmid H, Banas B, Kalaydjiev S, Busch DH, Pfeffer K, Mampaso F, Schlöndorff D, Luckow B.
    J Am Soc Nephrol; 2005 Dec 01; 16(12):3592-601. PubMed ID: 16267157
    [Abstract] [Full Text] [Related]

  • 33. Complement gene expression in hepatic and extrahepatic tissues of NZB and NZB x W (F1) mouse strains.
    Passwell JH, Schreiner GF, Wetsel RA, Colten HR.
    Immunology; 1990 Oct 01; 71(2):290-4. PubMed ID: 2228028
    [Abstract] [Full Text] [Related]

  • 34. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival.
    Mannoor K, Matejuk A, Xu Y, Beardall M, Chen C.
    J Immunol; 2012 Apr 15; 188(8):3628-38. PubMed ID: 22407922
    [Abstract] [Full Text] [Related]

  • 35. IK cytokine ameliorates the progression of lupus nephritis in MRL/lpr mice.
    Muraoka M, Hasegawa H, Kohno M, Inoue A, Miyazaki T, Terada M, Nose M, Yasukawa M.
    Arthritis Rheum; 2006 Nov 15; 54(11):3591-600. PubMed ID: 17075801
    [Abstract] [Full Text] [Related]

  • 36. C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist.
    Bao L, Osawe I, Puri T, Lambris JD, Haas M, Quigg RJ.
    Eur J Immunol; 2005 Aug 15; 35(8):2496-506. PubMed ID: 16052609
    [Abstract] [Full Text] [Related]

  • 37. Endothelial nitric oxide synthase reduces crescentic and necrotic glomerular lesions, reactive oxygen production, and MCP1 production in murine lupus nephritis.
    Gilkeson GS, Mashmoushi AK, Ruiz P, Caza TN, Perl A, Oates JC.
    PLoS One; 2013 Aug 15; 8(5):e64650. PubMed ID: 23741359
    [Abstract] [Full Text] [Related]

  • 38. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.
    Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA.
    Proc Natl Acad Sci U S A; 1996 Aug 06; 93(16):8563-8. PubMed ID: 8710910
    [Abstract] [Full Text] [Related]

  • 39. The SLAM family member CD48 (Slamf2) protects lupus-prone mice from autoimmune nephritis.
    Koh AE, Njoroge SW, Feliu M, Cook A, Selig MK, Latchman YE, Sharpe AH, Colvin RB, Paul E.
    J Autoimmun; 2011 Aug 06; 37(1):48-57. PubMed ID: 21561736
    [Abstract] [Full Text] [Related]

  • 40. Semaphorin3A: A Potential Therapeutic Tool for Lupus Nephritis.
    Bejar J, Kessler O, Sabag AD, Sabo E, Itzhak OB, Neufeld G, Vadasz Z.
    Front Immunol; 2018 Aug 06; 9():634. PubMed ID: 29670620
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.